Chemoendocrine therapy shows a greater negative association with patient-reported cognitive decline than endocrine therapy ...

"These findings from a mouse study likely have implications for humans. Men planning to have children should consider ...

At the San Antonio Breast Cancer Symposium, investigators reported phase III results showing that the oral selective estrogen ...

Scientists are increasingly blunt about a habit that once felt harmless: heating leftovers in plastic. As research on ...

In the CAPItello-291 trial of capivasertib plus fulvestrant, 73% of patients had already received a CDK4/6 inhibitor. As ...

Menopause represents a profound systemic shift involving cardiovascular, skeletal, and neurological health, requiring tailored clinical intervention.

In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen ...

Giredestrant, a selective estrogen receptor antagonist and degrader given as an adjuvant therapy, shows significant improvement in invasive disease-free survival (iDFS) in patients with early-stage, ...

The investigational, oral selective estrogen receptor degrader (SERD) giredestrant given as an adjuvant therapy showed significant improvement in invasive disease-free survival (iDFS) compared with ...

Because right now it is sort of the wild west, where people can kind of make up any sort of claim.” We've tapped experts to bring some clarity to the table. Keep reading for the five must-know facts ...

Asal Shirazi, Founder of ASA Foundation, shares insights into what drives inflammatory responses, including the role of ...

Tukysa, combined with Herceptin and Perjeta, extends progression-free survival in HER2+ metastatic breast cancer, showing ...